Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Canola oil may tame metabolic syndrome, study hints

NCT ID NCT01890330

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether eating canola oil every day for 12 weeks can improve cholesterol, blood vessel function, and other risk factors in people with metabolic syndrome. Eighty adults with the condition were randomly assigned to consume either canola oil or a typical Western fat blend. Researchers measured changes in blood fats and artery health to see if canola oil offers any advantage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Canola oil
What this could lead to
If it works, this could point toward a simple dietary change to help manage metabolic syndrome and reduce heart disease risk.
What could go wrong
This is a small, early-stage dietary study with only 80 participants. Results may not apply to everyone, and any benefits are likely modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Start date

Jul 2013

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male, or non-pregnant, non-lactating females, aged 20 - 75 years; 2. LDL-Cholesterol \>2.5 mmol/L and \<5.0 mmol/L 3. If the participant has 2 or more of the following characteristics of MetS * Fasting blood glucose \>5.6 mmol/L and \<7.0 mmol/L; * Blood pressure \>130/85 mm Hg and \<150/100; * Triglycerides \>1.7 mmol/L and \<4.0 mmol/L; * HDL-cholesterol \<1.0 mmol/L in males or \<1.3 mmol/L in females; * Abdominal obesity as defined by a waist circumference of \>102 cm (40 inches) in males and \>88 cm (35 inches) in females of non-Asian ethnicity, and a waist circumference of \>94 cm (37 inches) in males and \>80 cm (32 inches) in females of Asian ethnicity. 4. Able to read, write and communicate orally in English; 5. Willing to maintain a stable level of activity during participation in the study; 6. Willing to maintain dietary routine, refrain from consuming omega-3 supplements or omega-3 rich foods (\>0.3 grams ALA/serving or, \>0.1 grams of EPA and DHA; see handout with examples) and refrain from taking any over-the-counter medications or herbal supplements specified for weight loss, or the lowering of blood lipids, blood glucose or blood pressure from acceptance into the study until the final study visit; 7. Willing to comply with protocol requirements and procedures; 8. Willing to provide written informed consent. Exclusion Criteria: 1. Use of prescribed medications for lowering or managing blood lipids (hyperlipidemia), blood glucose (hyper/hypoglycemia), blood pressure (hypertension) or body weight; 2. Regular use of non-prescription products, over-the-counter medications, or herbal supplements designed to lower blood lipids, blood glucose, blood pressure or body weight, or omega-3 supplements or omega-3 rich foods, within the past 3 months; 3. Participating in or adhering to a weight loss diet or physical activity program designed to facilitate weight loss. 4. Adhering to a physician or dietitian directed lifestyle or dietary modification program for the purpose of lowering hypercholesterolemia; 5. Medical history of liver disease, with the exception of fatty liver, or chronic renal disease; 5\. Any acute medical condition or surgical intervention within the past 3 months; 6. Conditions or medications which are likely to increase the risk to the participants or study personnel, or to reduce the ability of the participant to comply with the protocol, or affect the results; 7. History of gastrointestinal reactions or allergies to canola oil or to one or more ingredients in the study foods which significantly limits the number of study foods that can be consumed; and 8. Currently participating in or having participated in a food intervention study within the last 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • St. Boniface General Hospital - I.H. Asper Clinical Research Institute

    Winnipeg, Manitoba, R2H 2A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.